UnknownPhase 4

Endoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding

China60 participantsStarted 2022-02-10

Plain-language summary

Remazolam besylate was used for sedation during endoscopic hemostasis in patients with esophageal and gastric varices rupture and bleeding in liver cirrhosis. The onset time, recovery time and incidence of adverse reactions were observed.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with bleeding from ruptured esophageal and gastric varices * Endoscopic hemostatic treatment was performed * Body Mass Index(BMI)18～28kg/m2 Exclusion Criteria: * History or evidence of increased risk of sedation/anesthesia; * Pregnant and lactating women; * Have participated in other drug trials within 30 days prior to enrollment; * those with contraindications to propofol, opioids and their remedies; * Unwilling to sign informed consent.

What they're measuring

Sedation scores

Timeframe: From the begin to 48 hours after procedure

Trial details

NCT IDNCT05554965

SponsorRenmin Hospital of Wuhan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-10-30

Contact for this trial

Lu Wang

15927142942 410669243@qq.com

View on ClinicalTrials.gov More Endoscopic Hemostasis trials